Observational Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Oct 7, 2019; 25(37): 5676-5686
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5676
Figure 1
Figure 1 Study flow chart. IBD: Inflammatory bowel disease; HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; NAFLD: Nonalcoholic fatty liver disease.
Figure 2
Figure 2 Nonalcoholic fatty liver disease patients showed a significantly longer disease remission compared to inflammatory bowel disease patients without nonalcoholic fatty liver disease. 33.9 mo vs 21.14, P < 0.05.